头孢克肟与其他口服抗生素对含BRO-1和BRO-2的成人卡他莫拉菌（布兰汉菌属）临床分离株及流感嗜血杆菌的活性比较。
Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae.
作者信息
Nash D R, Flanagan C, Steele L C, Wallace R J
机构信息
Department of Microbiology, University of Texas Health Center, Tyler 75710.
出版信息
Antimicrob Agents Chemother. 1991 Jan;35(1):192-4. doi: 10.1128/AAC.35.1.192.
Abstract
MICs of 10 oral antibiotics were determined for 105 Moraxella catarrhalis and 96 Haemophilus influenzae isolates from adults. A two- to fourfold increase in MICs of oral cephalosporins was seen in the presence of BRO-1 but not with TEM-1 or BRO-2. The MICs of cefixime for 90% of strains of H. influenzae (0.125 microgram/ml) and M. catarrhalis (0.25 microgram/ml) were 8- to 64-fold lower than those of other oral cephalosporins.
摘要
对从成人中分离出的105株卡他莫拉菌和96株流感嗜血杆菌测定了10种口服抗生素的最低抑菌浓度（MIC）。在存在BRO - 1的情况下，口服头孢菌素的MIC出现了2至4倍的增加，但在存在TEM - 1或BRO - 2的情况下则未出现这种情况。90%的流感嗜血杆菌菌株（0.125微克/毫升）和卡他莫拉菌菌株（0.25微克/毫升）对头孢克肟的MIC比其他口服头孢菌素低8至64倍。
相似文献
1
Comparison of the activity of cefixime and activities of other oral antibiotics against adult clinical isolates of Moraxella (Branhamella) catarrhalis containing BRO-1 and BRO-2 and Haemophilus influenzae.
Antimicrob Agents Chemother. 1991 Jan;35(1):192-4. doi: 10.1128/AAC.35.1.192.
2
In vitro activity of ceftibuten against Haemophilus influenzae and Branhamella catarhallis.
Diagn Microbiol Infect Dis. 1991 Jan-Feb;14(1):75-7. doi: 10.1016/0732-8893(91)90092-t.
3
In vitro activity of BAY v 3522, a new oral cephalosporin tested against Haemophilus influenzae and Branhamella catarrhalis.
Diagn Microbiol Infect Dis. 1990 Jul-Aug;13(4):349-52. doi: 10.1016/0732-8893(90)90030-y.
4
5
Effect of inoculum size on the in-vitro susceptibility to beta-lactam antibiotics of Moraxella catarrhalis isolates of different beta-lactamase types.
J Med Microbiol. 1994 Apr;40(4):252-5. doi: 10.1099/00222615-40-4-252.
6
Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002.
Antimicrob Agents Chemother. 2003 Jun;47(6):1875-81. doi: 10.1128/AAC.47.6.1875-1881.2003.
7
In-vitro activity of amoxycillin/clavulanic acid and five other oral antibiotics against clinical isolates of Haemophilus influenzae and Branhamella catarrhalis.
J Antimicrob Chemother. 1988 Dec;22(6):867-72. doi: 10.1093/jac/22.6.867.
8
In vitro activity of BAY v 3522, a new oral cephalosporin.
Antimicrob Agents Chemother. 1990 Sep;34(9):1855-7. doi: 10.1128/AAC.34.9.1855.
9
Antibiotic resistance among clinical isolates of Haemophilus influenzae in the United States in 1994 and 1995 and detection of beta-lactamase-positive strains resistant to amoxicillin-clavulanate: results of a national multicenter surveillance study.
Antimicrob Agents Chemother. 1997 Feb;41(2):292-7. doi: 10.1128/AAC.41.2.292.
10
Killing kinetics of five orally administered antibiotics at clinically achievable concentrations against Moraxella catarrhalis.
Eur J Clin Microbiol Infect Dis. 1992 Oct;11(10):923-6. doi: 10.1007/BF01962375.
引用本文的文献
1
Moraxella catarrhalis outer membrane vesicles carry β-lactamase and promote survival of Streptococcus pneumoniae and Haemophilus influenzae by inactivating amoxicillin.
Antimicrob Agents Chemother. 2011 Aug;55(8):3845-53. doi: 10.1128/AAC.01772-10. Epub 2011 May 16.
2
Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.
Eur J Clin Microbiol Infect Dis. 1998 Apr;17(4):219-34. doi: 10.1007/BF01699978.
3
Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.
Drugs. 1996 Jul;52(1):125-58. doi: 10.2165/00003495-199652010-00009.
4
Cefixime. A review of its therapeutic efficacy in lower respiratory tract infections.
Drugs. 1995 Jun;49(6):1007-22. doi: 10.2165/00003495-199549060-00010.
本文引用的文献
1
Comparative in vitro activity and beta-lactamase stability of FR 17027, a new orally active cephalosporin.
Antimicrob Agents Chemother. 1984 Aug;26(2):174-80. doi: 10.1128/AAC.26.2.174.
2
Homogeneity of transferable tetracycline-resistance determinants in Haemophilus species.
J Infect Dis. 1984 Jun;149(6):1028-9. doi: 10.1093/infdis/149.6.1028.
3
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria.
Diagn Microbiol Infect Dis. 1986 Jul;5(2):151-62. doi: 10.1016/0732-8893(86)90117-3.
4
Influence of growth medium and supplement on growth of Haemophilus influenzae and on antibacterial activity of several antibiotics.
J Clin Microbiol. 1987 Apr;25(4):650-5. doi: 10.1128/jcm.25.4.650-655.1987.
5
Isoelectric focusing of beta-lactamases from sputum and middle ear isolates of Branhamella catarrhalis recovered in the United States.
Drugs. 1986;31 Suppl 3:48-54. doi: 10.2165/00003495-198600313-00012.
6
Susceptibility of multiply resistant Haemophilus influenzae to newer antimicrobial agents.
Diagn Microbiol Infect Dis. 1988 Jan;9(1):27-32. doi: 10.1016/0732-8893(88)90057-0.
7
In vitro activity of cefixime (CL284635) and other antimicrobial agents against Haemophilus isolates from pediatric patients.
Chemotherapy. 1988;34(1):30-5. doi: 10.1159/000238544.
8
Ampicillin, tetracycline, and chloramphenicol resistant Haemophilus influenzae in adults with chronic lung disease. Relationship of resistance to prior antimicrobial therapy.
Am Rev Respir Dis. 1988 Mar;137(3):695-9. doi: 10.1164/ajrccm/137.3.695.
9
In vitro activity of new antibiotics against Haemophilus influenzae.
Eur J Clin Microbiol Infect Dis. 1988 Dec;7(6):812-4. doi: 10.1007/BF01975058.
10
Comparative, multicenter studies of cefixime and amoxicillin in the treatment of respiratory tract infections.
Am J Med. 1988 Sep 16;85(3A):6-13. doi: 10.1016/0002-9343(88)90457-3.
Zotero 插件